News - Adasuve, Perjeta

Filter

Current filters:

AdasuvePerjeta

Popular Filters

1 to 25 of 26 results

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Planned expansion of anti-psychotic drug throughout Europe

29-10-2013

Austrian drugmaker AOP Orphan and privately held Spanish drugmaker Ferrer Internacional are expanding…

AdasuveAOP OrphanEuropeFerrer InternacionalMarkets & MarketingNeurologicalPharmaceutical

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Ferrer and Medivir join forces on Adasuve for Nordic markets

19-09-2013

Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

Chugai launches Perjeta for breast cancer in Japan

13-09-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has launched the anti-cancer agent Perjeta (pertuzumab)…

Asia-PacificChugai PharmaceuticalMarkets & MarketingOncologyPerjetaPharmaceutical

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

UK NICE guidance says breast cancer drug Perjeta not value for money

06-08-2013

The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…

BiotechnologyEuropeOncologyPerjetaPharmaceuticalPricingRegulationRoche

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Alexza deal with Teva sets stage for Adasuve, say analysts

23-05-2013

USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical…

AdasuveAlexza PharmaceuticalAZ-002FinancialLicensingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Roche granted EU approval for Perjeta; board appointments

06-03-2013

The European Medicines Agency has approved Swiss drug major Roche's (ROG: SIX) Perjeta (pertuzumab) for…

BiotechnologyEuropeManagementOncologyPerjetaPharmaceuticalRegulationRoche

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

New entrants from Roche and Novartis will drive breast cancer market

20-08-2012

Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

FDA sets PDUFA date for Alexza's resubmission for Adasuve

08-07-2012

Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Alexza rockets on re-submission of Adasuve NDA

25-06-2012

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) saw its shares soar 44.9% to close at $3.97 on Friday,…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

FDA backs Roche's personalized breast cancer therapy Perjeta

11-06-2012

The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies

07-05-2012

California, USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) revealed last week that it has received another…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved

25-01-2012

US drug firm Alexza Pharmaceuticals (Nasdaq: ALXA) says that the US Food and Drug Administration will…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

1 to 25 of 26 results

Company Spotlight

Fibrotech

Fibrotech

Back to top